Compare Novartis AG (NVS) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs J M Smucker Co — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while J M Smucker Co trades at $123.61 (market cap $13.17B). The key difference: Novartis AG is far larger — about 19.9× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVS | SJM | |
|---|---|---|
Market Cap | $262.28B | $13.17B |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $132.34 |
52-Week Low | $121.80 | $89.53 |
Enterprise Value | $303.60B | $20.03B |
Dividend Yield | 3.45% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
SJM trades at $124.66, down 1.13% on the day, with a bullish technical signal from moving averages but bearish oscillators. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.24 surpassing the $2.22 estimate. The company reported a net loss of $1.23 billion for 2025, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $144.78 price target, indicating potential upside. A dividend of $1.12 per share is scheduled for payment on September 1, 2026.
The outlook is cautiously optimistic, driven by strong earnings performance and raised guidance, but high valuation ratios and recent insider sales pose risks. Debt levels remain elevated with a debt-to-asset ratio of 43.71% in 2025. Investors should weigh robust operational cash flow against margin pressures and competitive challenges in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
